title: Endometrial cancers in postmenopausal breast cancer patients with tamoxifen treatment.
abstract: To evaluate possible predicting factors for endometrial cancer in postmenopausal breast cancer patients with tamoxifen treatment, we compared various clinical features between 12 postmenopausal breast cancer tamoxifen-treated patients with endometrial cancer and a control group of 261 otherwise similar patients without this endometrial pathology. These comparisons were based on a long-term prospective follow-up. Several clinical factors such as longer duration of breast disease, older patient age, lower frequency of chemotherapy administration, and higher frequency of postmenopausal bleeding were found among the tamoxifen-treated patients with endometrial cancers, and were significantly different when compared to the control group. Only eight (66.7%) had postmenopausal bleeding, and a preoperative diagnosis of endometrial cancer was made in only six (50.0%). When considering postmenopausal bleeding as a marker for endometrial cancer in the study patients, sensitivity was 67% and specificity was 98%.
authors.affiliation: Department of Obstetrics and Gynecology, Tel Aviv University, Ramat-Aviv, Israel.
authors.forename: I
authors.initials: I
authors.lastname: Cohen
authors.forename: R
authors.initials: R
authors.lastname: Azaria
authors.forename: A
authors.initials: A
authors.lastname: Fishman
authors.forename: R
authors.initials: R
authors.lastname: Tepper
authors.forename: J
authors.initials: J
authors.lastname: Shapira
authors.forename: Y
authors.initials: Y
authors.lastname: Beyth
mesh_terms: D018195:Adenosarcoma / Q000175:diagnosis / Q000453:epidemiology; D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000175:diagnosis / Q000453:epidemiology; D003710:Demography; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D004717:Endometrium / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000453:epidemiology; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013629:Tamoxifen / Q000627:therapeutic use*; D013997:Time Factors; D014592:Uterine Hemorrhage / Q000175:diagnosis
chemical_list: D013629:Tamoxifen